H
Hanif Shaikh
Researcher at International Vaccine Institute
Publications - 7
Citations - 498
Hanif Shaikh is an academic researcher from International Vaccine Institute. The author has contributed to research in topics: Rotavirus vaccine & Vaccine efficacy. The author has an hindex of 5, co-authored 5 publications receiving 397 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial.
Nita Bhandari,Temsunaro Rongsen-Chandola,Ashish Bavdekar,Jacob John,Kalpana Antony,Sunita Taneja,Nidhi Goyal,Anand Kawade,Gagandeep Kang,Sudeep Singh Rathore,Sanjay Juvekar,Jayaprakash Muliyil,Alok Arya,Hanif Shaikh,Vinod Joseph Abraham,Sudhanshu Vrati,Michael A. Proschan,Robert Kohberger,Georges Thiry,Roger I. Glass,Harry B. Greenberg,George Curlin,Krishna Mohan,G.V.J.A. Harshavardhan,Sai Prasad,T.S. Rao,John W. Boslego,Maharaj K. Bhan +27 more
TL;DR: Monovalent human-bovine (116E) rotavirus vaccine is effective and well tolerated in Indian infants, and prevalence of immediate, solicited, and serious adverse events was similar in both groups.
Journal ArticleDOI
Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life
Nita Bhandari,Temsunaro Rongsen-Chandola,Ashish Bavdekar,Jacob John,Kalpana Antony,Sunita Taneja,Nidhi Goyal,Anand Kawade,Gagandeep Kang,Sudeep Singh Rathore,Sanjay Juvekar,Jayaprakash Muliyil,Alok Arya,Hanif Shaikh,Vinod Joseph Abraham,Sudhanshu Vrati,Michael A. Proschan,Robert Kohberger,Georges Thiry,Roger I. Glass,Harry B. Greenberg,George Curlin,Krishna Mohan,G.V.J.A. Harshavardhan,Sai Prasad,T.S. Rao,John W. Boslego,Maharaj K. Bhan +27 more
TL;DR: The sustained efficacy of the 116E in the second year of life is reassuring and the overall incidence of severe RVGE per 100 person years was 1.3 in the vaccine group and 2.9 in the placebo recipients.
Journal ArticleDOI
A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants
Prasad S. Kulkarni,Sajjad Desai,Tushar Tewari,Anand Kawade,Nidhi Goyal,Bishan S Garg,Dinesh Kumar,Suman Kanungo,Veena Kamat,Gagandeep Kang,Ashish Bavdekar,Sudhir Babji,Sanjay Juvekar,Byomkesh Manna,Shanta Dutta,Rama Angurana,Deepika Dewan,Abhijeet Dharmadhikari,Jagdish Kamalaji Zade,Rajeev M. Dhere,Alan Fix,Maureen Power,Vidyasagar Uprety,Varsha Parulekar,Iksung Cho,Temsunaro Rongsen Chandola,Vikash K. Kedia,Abhishek V Raut,Jorge Flores,Hanif Shaikh,Lalit Gupta,Rakesh Patil,Mohd. Aslam,Alok Arya,Farhana Afzal Rafiqi,Subodh S Gupta,Chetna Maliye,P. V. Bahulekar,Kiran Bala,Tajali Nazir Shora,Shahid Hussain,Mihir K. Bhattacharya,Ashis K. Mukhopadhyay,Dilipkumar Pal,Jayanta K. Saha,Ranjitha S Shetty,Muralidhar M Kulkarni,Chythra V. Raj +47 more
TL;DR: The Pentavalent reassortant rotavirus vaccine showed excellent tolerability and a good safety profile when tested for efficacy in infants and the intent to treat analyses confirmed all the per protocol analyses.
Journal ArticleDOI
Current and future cholera vaccines.
TL;DR: The global demand for OCV has been boosted by the WHO recommendation to use OCV and has been increasing due to the availability of cheaper easy-to-use vaccines, feasibility of mass OCV vaccination campaigns, demonstration of protection to underserved population in precarious situations, and vaccine costs being borne by Gavi.
Journal ArticleDOI
Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead.
Khalid Ali Syed,Tarun Saluja,Heeyoun Cho,Amber Hsiao,Hanif Shaikh,T. Anh Wartel,Vittal Mogasale,Julia Lynch,Jerome H. Kim,Jean-Louis Excler,Sushant Sahastrabuddhe +10 more
TL;DR: This review provides an overview of the licensed typhoid vaccines and vaccine candidates under development, and the challenges ahead for introduction.